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Abstract 
The sense of hearing is essential for permitting human beings to interact with the environment and its dysfunctions can 
strongly impact on the quality of life. In this context, the cochlea plays a fundamental role in the transformation of the 
airborne sound waves into electrical signals, which can be processed by the brain. However, several diseases and external 
stimuli (e.g., noise, drugs) can damage the sensorineural structures of cochlea, inducing progressive hearing dysfunctions 
until deafness. In clinical practice, the current pharmacological approaches to treat cochlear diseases are based on the almost 
exclusive use of systemic steroids. In the last decades, the efficacy of novel therapeutic molecules has been proven, taking 
advantage from a better comprehension of the pathological mechanisms underlying many cochlear diseases. In addition, the 
feasibility of intra-tympanic administration of drugs also permitted to overcome the pharmacokinetic limitations of the 
systemic drug administration, opening new frontiers in drug delivery to cochlea. Several innovative drug delivery systems, 
such as in situ gelling systems or nanocarriers, were designed and their efficacy has been proven in vitro and in vivo cochlear 
models. The current review aims to describe the art of state in the cochlear drug delivery, highlighting lights and shadows 
and discussing the most critical aspects still pending in the field. 
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1 Introduction 
The hearing is one of the most important senses of a human body, since it is strongly involved in the ability of humans to 
communicate each other. Airborne sounds are collected by a complex anatomical structure, the ear, and translated into 
electrical signals, which are sent to the occipital lobes of the brain to be processed. According to its anatomy, the ear is 
conventionally divided in three parts: the outer, middle and inner ear. The cochlea is the part of inner ear dedicated to the 
hearing; taking advantage from its snail-shell-like structure, it can convert the mechanical stimuli coming from the middle 
ear to electrical signals.  
The cochlea functionality may be affected by external stimuli (e.g., loud sounds), infections and diseases, which induce 
alterations of hearing (e.g., tinnitus) and/or reduction of hearing capacity until hearing loss [1, 2]. However, few medicinal 
products are currently authorized for cochlear indication in humans [3, 4]. Efficacious drug concentration in the cochlea 
cannot be easily reached due to the ear anatomy. Similarly, the local drug administration through the outer ear cannot be 
provided, due to the vacuum space in the middle ear. To overcome this limitation, intra-tympanic and intra-cochlear 
injections are the only possibilities to locally administer therapeutics [4]. In this context, the most promising approaches to 
improve the drug concentration at the therapeutic site or to decrease the dose regimen appear in situ gelling systems, or 
nanosystems for delivering drugs and macromolecules. The need to develop drug delivery systems and novel techniques of 
administration by these routes is also associated with the identification of novel therapeutic candidates and the study of the 
cochlear drug distribution. 
Based on these premises, the review describes the most critical features of the anatomy and physiology of the inner ear that 
should be taken in consideration during the design of drug delivery systems intended to be administered by the intra-
tympanic route. The in vitro and in vivo efficacy of several drug substances and drug delivery systems in restoring the 
physiological functionality of cochlea are discussed based on the articles found in PubMed and Scopus databases. The 
analysis of information on cochlear implants, other medical devices and available diagnostic tools is outside the aim of the 
review. However, the reader can refer to other reviews available in literature [5, 6, 7, 8]. 
2 Anatomy of inner ear 
The ear structure is conventionally divided in three parts: the outer, middle and inner ear (Figure 1). The outer ear is formed 
by the auricle, which is the external part of the ear, and the ear channel. Directly in contact with the external environment, 
this structure amplifies and directs the sound waves from the air to the tympanic membrane, also called eardrum. Placed as 
separation of the outer ear to the middle ear (i.e., tympanic cavity), the eardrum is a complex membrane formed by three 
different tissue layers [9] It is enough flexible to vibrate when stimulated by the sound waves and to translate them in 
mechanical movements to three ossicles that are in the tympanic cavity: the malleus, the incus and the stapes. The function 
of these bones is to transfer the mechanical signals induced by the tympanum vibration to the oval window, one of the two 
openings between the middle and the inner ear. Since the oval window membrane (OWM) is smaller than the tympanic 
membrane, the vibrations induced by the ossicles movements result amplified when arrive in the inner ear. The cochlea is 
the part of the inner ear where the mechanical stimuli are translated into electrical signals and, then, sent through the auditory 
nerves to the occipital lobe of the brain for being processed. High frequencies are detected in the basal region of the cochlea 
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(max 20,000 Hz), whereas low frequencies (100 Hz) near to the helicotrema, which is the apical part of cochlea [10]. The 
cochlear system can absolve this complex function taking advantage from a snail-shell-like structure that includes three 
compartments: the scala vestibuli, the scala media and the scala tympani. The scala vestibuli is in direct contact to the 
OWM and is filled by perilymph, an extracellular fluid with a composition of electrolytes like plasma. The perilymph 
volume corresponds to the 90% of the total fluid space of cochlea (≈ 84 μL) [11]. The scala tympani originates from the 
scala vestibuli near to the helicotrema and ends at the round window, the second opening of the inner ear to the cavity of 
middle ear. The scala media is located between the two other compartments and contains the organ of Corti, which is the 
sensory organ of the hearing. The scala media is separated from the scala vestibuli by the Reissner’s membrane and from 
the scala tympani by the basal membrane. Unlike other cavities, the scala media is filled by endolymph, which differs from 
perilymph of the higher concentration of potassium ions and the lower of sodium [12]. The different composition of 
perilymph and endolymph guarantees a positive electric potential of 80-90 mV. The conservation of such electric potential 
is essential for the correct transduction of mechanical waves in electrical signals and is guaranteed by the negligible 
permeability of both the Reissner’s and basal membranes and the existence of a sophisticated barrier between endolymph 
and blood given by the stria vascularis [13]. Indeed, the blood-cochlear barrier, which is likely the blood-brain barrier, is 
constituted by a continuous capillary endothelium characterized by tight junctions and no fenestrations. The organ of Corti 
located near the basal membrane of the scala media, is formed by the tectorial membrane, the supporting cells and the hair 
cells. The last ones are sensorial cells characterized by the presence of stereocilia in the apical surface and connected to 
nerve synapsis at the basal surface.  
When the sound waves induce the stapes movements, the generated perilymphatic waves transfer the vibrations to the basal 
membrane. The movement of the basal membrane determines the reduction of the gap between the hair cells and the tectorial 
membrane so that the deflection of stereocilia opens specific mechanical sensitive potassium ion channels in the apical part 
of the hair cells. The consequent depolarization and repolarization of hair cells permit the translation of the fluid wave 
movements into electrical signals, which are transferred through nerves to brain for being processed as sounds. 
3 Cochlear diseases and cellular therapeutic targets 
Considering the fine structures involved in the hearing process, several pathological mechanisms may cause an impairment 
on the functionality of cochlea. Indeed, infections [14], drugs [1], autoimmune diseases [15, 16], loud sounds [17 18], and 
other external stimuli [19] can affect its ability to transfer the mechanical signals induced by airborne sound waves and to 
process them in electrical stimuli. 
Infections are the most common diseases of the outer and middle ear because they are connected to the external environment 
and the oral cavity via Eustachian tube, respectively. Otitis media is one of the most frequent disease in infants and children 
[14]. Taking advantages from the differences in anatomical angles of Eustachian tubes of infants and children with respect 
to adults, bacteria of the oral cavity can colonize the cavity of middle ear inducing an inflammatory response. Besides the 
inflammation symptomatology, pain and risk of eardrum perforation [14], the otitis media can also cause sensorineural 
hearing loss and an enlargement of endolymphatic spaces, the so-called endolymphatic hydrops [20]. These cochlear 
complications seem related to the permeation through the round window membrane (RWM) of molecules and bactericidal 
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agents that can be ototoxic [21]. Indeed, several drugs are demonstrated to induce temporary or permanent cochlear 
dysfunctions, resulting in hearing loss [1]. Aminoglycoside antibiotics (e.g., streptomycin, gentamicin), nonsteroidal anti-
inflammatory drugs (e.g., salicylates), loop diuretics (e.g., furosemide) and chemotherapy agents (i.e., cisplatin and 
carboplatin) can alter the functionality of hair cells, although the toxic mechanism may vary according to the drug class. 
For instance, aminoglycoside antibiotics and cisplatin induce an imbalance in the reactive oxygen species (ROS) in the hair 
cell cytoplasm [22] and the activation of apoptosis pathways [23, 24]. The ototoxicity of furosemide is due to the interference 
with the enzymes involved in the ion transport in the stria vascularis, disrupting the barrier properties and altering the 
endolymph composition with a decrease of the endolymphatic potential [1]. 
The ROS balance can be also modified by stressful external stimuli, such as loud sounds and chronic noise exposure [17]. 
High levels of noise weight on the mitochondrial respiratory process of hair cells, producing an excess of free radicals able 
to alter the cytoplasmic redox balance [25]. In addition, several evidences also suggested that high-frequency sounds impact 
negatively on the stria vascularis functionality [17, 26], inducing a decrease of the endolymphatic potential [18]. Besides 
the above-mentioned therapeutic targets, different types of ion channels resulted involved in the regulation of ionic fluxes 
around cochlea [12]. Potassium voltage-gated ion channels (e.g., Kv3) and glutamate receptors are one of the most studied 
classes for restoring physiological electrical signaling from hair cells to neurons. Indeed, the former channels are directly 
involved in the repolarization of hair cells [27], whereas the latter ones are overstimulated in stressful conditions (e.g., noise, 
drugs), inducing a massive calcium influx in neurons [28]. Moreover, nicotinic receptors can be potential candidates for 
limiting the toxic effects induced by noise [29]. Nicotinic cholinergic receptors, (i.e., α9α10 type) are present on the basal 
surface of hair cells, near to the synapses of the olivocochlear neurons. These neurons are involved in the amplification of 
sound signaling recorded by hair cells. They can positively modulate the sensitivity of hair cells for sounds, separating them 
from the background noise and protecting from loud sounds. The activation of α9α10 receptors increases the intracellular 
calcium concentration, inducing the inhibition of hair cells [30]. The blockage of these receptors can also meliorate the 
control of tinnitus, which is an auditory phantom sensation of ringing in the ears recognized as one of the first clinical signs 
of damage of the cochlear system [31, 32]. 
The hearing process can be also affected by immune-mediated diseases [15, 16] and other pathologies with elusive etiology 
[2]. Among them, Ménière’s disease affects both the vestibular and the cochlear part of inner ear. Its physiopathology seems 
to be related to the dysfunction in the endolymph homeostasis resulting in the endolymphatic hydrops [33]. The mechanical 
stress induced by the increase in endolymph volume is toxic for the organ of Corti, inducing sensorineural hearing loss and 
tinnitus. Although the etiopathological mechanism is still unclear, literature evidences suggest an abnormal reduction of 
endolymph clearance mediated by vasopressin [34]. Indeed, such a hormone controls in physiological conditions the water 
movements through the endolymphatic sac and the stria vascularis by the modulation of aquaporin expression due to the 
activation of vasopressin type 2 receptors [35, 36]. 
4 Pharmacokinetics in cochlea and route of administrations 
The topical and systemic administration of drugs in the cochlea presents several criticisms due to the peculiar anatomical 
and histological structures. Indeed, the local drug administration in outer ear results only effective for treating diseases of 
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the outer and middle ear, without reaching therapeutic drug concentrations in cochlear compartments (e.g., perilymph, 
endolymph) due to the presence of the vacuum of tympanic cavity. The systemic administration presents some issues in the 
drug distribution. Firstly, the distribution volume of cochlea is limited in comparison to the other physiological 
compartments, requiring an increase of the administered dose to reach efficacious levels in the scala media. Secondly, the 
blood-perilymph barrier given by the stria vascularis can also limit the drug distribution in the cochlea [13]. Large and 
highly charged molecules cannot permeate this barrier, especially in the case of positive charged molecules due to the 
endolymph potentials [13]. Therefore, the design of a local drug delivery systems is highly desired [5]. Intracochlear drug 
delivery systems are intended to be injected directly into the cochlear fluids bypassing the absorption step, but their design 
is critical due to the risk of perilymph leakage from the injection hole and the possible access to the cerebrospinal fluid [37]. 
Conversely, the intra-tympanic administration seems to be more promising because of the drug product is deposited in the 
tympanic cavity near to the RWM niche. Although RWM seems to be the main gate of access of drugs to the cochlea from 
the middle ear, some studies suggested that drug amount could also reach the cochlea via OWM [5, 38]. Thus, it is worthy 
of underline that an intra-tympanic drug delivery system should be designed in order to improve the resistance time in the 
tympanic cavity and to facilitate the drug permeation process through RWM or OWM [5]. Analogously to the eardrum, the 
RWM is formed by three layers: an outer epithelium in contact with the middle ear cavity, a connective layer and a squamous 
epithelium facing the inner ear [21]. The OWM has a similar histology as well. Despite its complex structure, some studies 
conducted in vivo on animal models suggested that RWM acted as semipermeable membrane. Traces of different types of 
drugs (e.g., antibiotics, toxin, albumin, anesthetics), or micro- and nano-particles could be found in the cochlear fluids after 
an intra-tympanic injection [39-42]. The overall results suggested that several physical or chemical proprieties of molecules 
or particles could influence the permeation through the RWM via intercellular pathways. The higher the particle size (or the 
molecular volume), the lower the penetration rate; whereas cationic molecules seem to permeate through the RWM better 
than anionic ones [41, 43]. In addition, recent published evidences suggested that drug/nanosystem permeation process 
could be also promoted by endocytosis pathways at the surface of epithelial layer of RWM or OWM [5]. Once a molecule 
or a particle is in the perilymph, it can reach all the cochlear compartments by passive diffusion through the perilymphatic 
fluid and partitioning through the cochlear tissues in the different scala. For a more complete description of the 
pharmacokinetic model of cochlea, the reader is invited to refer to works of Salt and co-workers [4, 44]. 
5 Therapeutic molecules 
The gold standard in the clinical management of cochlear diseases remains the intra-tympanic or systemic administration 
of steroids [44, 45]. Dexamethasone is currently recommended in the treatment of several diseases, such as Ménière’s 
disease [45], endolymphatic hydrops [46], tinnitus [47] and sudden sensorineural hearing loss [3]. However, the efficacy of 
both local and systemic steroids in treating cochlear diseases is still matter of debate in medical community, since it has not 
always supported by extensive and univocal clinical evidences [3, 48, 49]. 
In the last decades, many efforts were made to propose strategies for preventing the ototoxicity induced by drugs and 
regenerating the sensorial and supporting cells functionality. Table 1 and Table 2 report the proof-of-efficacy of investigated 
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drugs in in vitro and in vivo models, respectively. For an in-depth analysis of the patents recently published on the topic, 
the reader is invited to refer to work of Nguyen and co-workers [6]. 
The better comprehension of etiopathological mechanism underlying cochlear dysfunctions opened new frontiers in 
cochlear treatments. Since the drug ototoxicity was mainly induced by the generation of ROS, the effectiveness of several 
antioxidant agents was tested in vitro [50-52] and in vivo on animal models [53-59] and human patients [60, 61]. For 
example, the local or systemic administration of resveratrol or N-acetylcysteine was demonstrated to protect both from 
drug-ototoxicity in animals (e.g., rats, guinea pigs and zebrafishes) [53, 54] and from noise and loud sounds [55]. However, 
the mechanism of action of antioxidants is not only limited to a direct effect on cochlear cell lines, as evident in the case of 
D-methionine and sodium thiosulfate: they prevented the cisplatin-induced ototoxicity, altering the cisplatin 
pharmacokinetics other than restoring the redox balance in cochlear system [57, 58, 61, 62].  
Besides antioxidants, other molecules were proposed to prevent the ROS mediated- and noise-mediated injuries [6, 63-67]. 
So and colleagues showed in vitro that flunarizine, a T-type calcium channel blocker, could increase the survival of organ 
of Corti cells exposed to cisplatin, inhibiting the influx of calcium ions and the lipid peroxidation induced by ROS generation 
and mitochondrial permeability transition [68]. Moreover, molecules able to modulate the function of ion channel were also 
investigated to restore the physiological electrolytes equilibrium in hair cells and neurons [6]. Activators of Kv3 channels 
were proposed for treating hearing loss since they are involved in the repolarization of hair cells. Inhibitors of such class of 
voltage-gated ion channel were studied to treat tinnitus. Molecules able to modulate the activation of nicotinic cholinergic 
and glutamate receptors were also matter of investigation due to their possible implication on electrical current transmission 
both in olivocochlear fibers and cochlear hair cells. Boffi and co-workers demonstrated that ascorbic acid acted in vitro as 
a partial agonist of α9α10 nicotinic cholinergic receptors [69]. Ketamine, a well-known anesthetic drug, resulted effective 
in reducing the overactivation of N-ethyl-D-aspartate receptors, limiting the toxicity in auditory neurons due to their 
overstimulation [6]. Another therapeutic strategy investigated for restoring the fitness of neuronal synapsis was the 
administration of growth factors to cochlea. Indeed, as shown by Suzuki and colleagues, intra-tympanic delivery of 
neurotrophin 3 could regenerate the neuronal connections with hair cells after synapses loss due to high sounds exposure 
[70]. 
The activation or inhibition of several intracellular metabolic pathways (e.g., Akt/Nrf-2, PI3K, ATM-Chk2-p53) also 
provided a better resistance of hair cells to damages [71-73]. For instance, the expression of NADPH oxidases was positive 
regulated by noise and the inhibition of their expression might be used as potential therapeutic management of cochlear 
damages [74]. In this context, the intra-tympanic administration of a short interfering RNA (siRNA) could reduce the 
expression of the NOX3 isoform of NADPH oxidase in cells of both organ of Corti and stria vascularis exposed to cisplatin 
[75]. Moreover, Du and colleagues highlighted that it was possible to regenerate the damaged hair cells using siRNA able 
to inhibit the expression of gene HES1 [76]. HES1 resulted involved in the down-regulation of the gene ATOH1, which 
encode for a transcription factor involved in differentiation of hair cell. Considering the potential applications in cochlear 
cell regeneration, many efforts were made for identifying new therapeutic candidates in modulating ATOH1 activation [6]. 
One of the most promising drug class for the promotion of hair cell regeneration are the inhibitors of γ-secretase, a protein 
involved in the activation of an inhibitory pathways of ATOH1. In addition, the use of complementary DNA (cDNA) was 
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also investigated to repair genetic dysfunction of hair cells. As an example, intracochlear injection of adenovirus AAV 
loaded with cDNA of WHRN demonstrated to be effective in restoring the physiological structure of stereocilia of hair cell 
in a mouse model [77]. However, such a therapeutic solution might be effective only if the sensorial cells resulted only 
damaged, not destroyed. Since cochlear tissue was not able to restore by itself, the transplantation of stem cells was recently 
studied to find solutions applicable also in the case of total disruption of hair cells [78]. In this optic, the both embryonic 
and pluripotent stem cells were proposed and investigated for replacing damaged hair cells, supporting cells and spinal 
ganglion neurons [79-81]. Starting from the demonstration that embryonic stem cells could recreate in vitro the 3D structure 
of sensorial epithelium of inner ear [79], several studies demonstrated the feasibility of stem cell transplantation via 
intracochlear injection in different animal models [81]. Although most of the studies showed a good viability and 
differentiation of stem cells after delivery, several criticisms remain on the round. Firstly, the targeting of the injected cells 
at the damaged part of the tissues is challenging as well as the regeneration of the complex structure of organ of Corti in 
vivo. Secondly, the current technologies are not able to targeting the differentiation of stem cells to preserve the 
physiological difference in morphological cellular organization in the different part of cochlea [78]. 
6 Drug delivery systems 
Even if the last decades were characterized by a growing interest to individuate novel therapeutics and technological 
approaches in the attempt to overcome the biopharmaceutical limitations of cochlea, relatively few information is available 
in literature. It mainly concerns the design of hydrogels, nanocarriers and their combinations. The most significant in vitro 
and in vivo proof-of-efficacy of drug delivery systems are summarized in Table 1 and Table 2, respectively. 
6.1 Hydrogels 
Although the intra-tympanic administration results more effective than systemic administration, the biodistribution in the 
cochlea is strongly influenced by clearance from the RWM surface. Indeed, it significantly reduces the drug residence time 
of a drug at the adsorption site, as demonstrated in the case of the intra-tympanic application of methylprednisolone [82]. 
In order to minimize the formulation wash-out from RWM, hydrogels formulations made of several natural polymers 
appeared particularly interesting even if the administrable volume is limited (max 0.4-0.6 mL) [6, 83-87]. The efficacy of 
this approach was demonstrated in case of hyaluronic acid hydrogel, which could be effective in controlling the delivery of 
dexamethasone in cochlea of guinea pigs after intra-tympanic administration [88]; as well as in the case of chitosan-based 
hydrogels containing dexamethasone and gentamicin [89, 90]. Moreover, hydrogels made of gelatin or cross-linked porcine 
type1-collagen were effective to deliver proteins, such as insulin-like [83, 86] and hepatocyte growth factors [85].  
However, in all these cases, the hydrogel viscosity has to be properly evaluated and selected on the basis of a compromise 
between the improvement of the resistance time at RWM niche and the injection in the tympanic cavity by a needle lower 
than G22 [5]. To overcome these limitations, in situ gelling systems, namely injectable formulations that form a macroscopic 
gel at the site of injection after a stimulus, have been investigated. Engleder et al. designed a thermosensitive hydrogel 
containing triamcinolone acetonide, taking advantage from the ability of poloxamer 407 to modify its viscosity as function 
of the temperature [87]. Such a formulation was a solution at room temperature, but it became a gel within few minutes 
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after RWM deposition due to the higher temperature of body (i.e., around 37°C). Moreover, Yu and co-workers showed 
that the cochlear distribution of dexamethasone could be significantly improved using a time-sensitive hydrogel made of 
regenerated silk and polyethylene glycol (PEG) [84]. Such a hydrogel maintained the sol form enough to be intra-tympanic 
injected before the sol-gel transition occurred. 
Besides the criticisms related to injectability, the technological properties of a hydrogel formulation should be also 
rationalized to minimize any side effects after deposition in the tympanic cavity. Indeed, some evidences in literature 
suggested that the intra-tympanic hydrogels could induce temporary decrease in hearing functionality, particularly when an 
excessive volume of hydrogel was injected in the tympanic cavity [91]. Such side effect was mainly due to a direct 
interference of hydrogel with the movements three ossicles and, in general, the auditory function was recovered within 7-
10 days because of formulation wash-out from the middle ear [92]. 
In addition, hydrogels were also studied as vehicles for intra-cochlear transplantations of stem cells and gene therapy [37, 
93]. Since the intra-cochlear injection required the use of needle of smaller diameter (e.g., G30-G36), the formulation 
viscosity resulted even more critical in comparison to intra-tympanic one. However, hydrogel might be more advantageous 
than solution for preventing the pressure fall in the inner ear due to the RWM perforations, with the risk of an efflux of 
cerebrospinal fluid through the cochlear aqueduct. Indeed, as demonstrated by Plontke and co-workers, the use of hyaluronic 
or poloxamer 407 hydrogels preserved the amount of fluorescein that was retained in perilymph of guinea pigs, taking 
advantage from their ability to seal the RWM perforation [37]. 
Finally, hydrogels found applications as coating of cochlear implants to prevent the fibrous tissue growth with a consequent 
worsening of the hearing functionality [94-97]. To avoid this possible side effect, steroid-loaded hydrogels made of 
poloxamer 407 were demonstrated to control the release of dexamethasone and prevent fibrous tissue growth in guinea pig 
model [95]. The use of modified alginate hydrogels was also proposed as coating of cochlear implant to effectively improve 
its biocompatibility and in vivo performances of the medical device [97].  
6.2 Nanocarriers 
The diffused interest for the therapeutic applications of nanotechnology has also driven the research to novel drug delivery 
systems intended for both intra-tympanic and intra-cochlear administration. Considering the ability of nanoparticles to 
control and target the drug release, polymeric nanoparticles [40, 98-106], lipid nanocapsules [107, 108], cubosomes [109], 
polyplexes [110, 111], metallic core nanoparticles [38, 112-115], liposomes [43, 116-118] and lipoplexes [119] were 
investigated in vitro and in vivo as drug-delivery systems or imaging agents.  
Although the high sensitivity of cochlear structures for external insults, such nanocarriers seem almost safe [107, 109]. As 
an example, the study of the impact of polymeric nanoparticles, made of poly(d,l lactide-co-glycolide) (PLGA) and poly(ε-
caprolactone)–poly(ethylene glycol) di-block (PCL-PEG), on the in vitro cell viability revealed that such nanocarriers were 
not toxic for both organ of Corti and stria vascularis cell lines [101]. This result was in agreement with the data provided 
by Yoon and co-workers on the biocompatibility of different types of oligoarginine-conjugated nanoparticles [103]. In vivo 
evidences seem to confirm the biocompatibility of polymeric nanocarriers, since they did not alter significantly the auditory 
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functionality of animal models [40, 116]. Analogously, the direct injection of cationic liposomes into guinea pig cochlea 
did not cause any inflammation or cytotoxic event [119]. 
Beside the safety profile, another attribute that should be considered as critical is the biodistribution of nanosystems. In fact, 
if the biodistribution of nanosystems in the cochlea is poor after systemic administration, the intra-cochlear injection is not 
easy to perform and only few evidences are reported regarding the efficacy of the drug delivery systems administered by 
such a route. As an example, Wareing and co-workers demonstrated the feasibility to use cationic liposomes for gene 
transfection in the cochlear tissue as an alternative to the viral vectors [119]. Indeed, although non-selectively, these 
nanocarriers could deliver exogenous gene to the spiral limbus, the spiral ganglia and to the organ of Corti after a direct 
injection into the inner ear. Besides these promising results, however, the intra-tympanic administration of therapeutics 
remains the most promising alternative [100]. 
Therefore, the ability of nanocarriers to permeate RWM becomes the most relevant critical issue to assure suitable drug 
concentration at the therapeutic site. As demonstrated by Ge et al. in chinchilla model, PLGA nanoparticles containing 
superparamagnetic iron oxides nanoparticles (SPION) could permeate the RWM and distribute in almost all cochlear 
compartments [106]. Aggregated clusters of nanoparticles were detected in the perilymph fluid and endolymphatic sac near 
to the organ of Corti. A similar cochlear distribution was also confirmed for other polymeric nanosystems tested in different 
animal models [40, 105, 109] and for lipid vesicles. The studies conducted by Zou et al. revealed the presence of intact 
vesicles in the perilymph after intra-tympanic injection and demonstrated that their permeation through the middle inner ear 
barriers was size dependent; it was higher for liposomes smaller than 100 nm [43]. In another study, the same research 
group concluded that RWM was the major pathway for liposome entrance into the inner ear and that liposomes could be 
retained in cochlea within 6 days after in vivo intra-tympanic administration [118]. Moreover, liposomes labelled with 
contrasting agent were traced by magnetic resonance imaging (MRI) after intra-cochlear and intra-tympanic administrations 
in rats and their distribution in the cochlea was observed within 1 hour [117]. Increasing the injected volume, distal portions 
of the inner ear were also reached by the functionalized nanoparticles, suggesting also a potential exploitation of these 
systems for vestibular drug delivery. 
Besides the obvious applications as imaging tools when loaded in polymeric nanoparticles or liposomes, SPION could be 
effectively used for promoting the permeation of drug through the RWM. As an example, Du and co-workers showed that 
the permeation of dexamethasone was two-time increased when SPION-loaded polymeric nanoparticles were used as drug 
carriers in presence of a magnetic field [115]. However, although such interesting biopharmaceutical performances and the 
possible application in theragnosis, the reduced biodegradability of SPION and the subsequent risk of side effect due to a 
prolonged biopersistence in cochlea resulted factors that might limit their future applications in humans as therapeutics 
[120]. 
The potentialities of drug-loaded nanocarriers in preventing cellular damages induced by ototoxic drugs or for cellular 
specific targeting were also demonstrated in several preliminary in vivo investigations [111]. Cai et al. showed that PLGA 
nanoparticles could be effectively used to load and intra-tympanic administer different active components present in extract 
of salvia miltiorrhiza and panax notogineng [104]. Moreover, Sun and co-workers demonstrated that dexamethasone loaded 
nanoparticles, made of poly(lactic acid) (PLA)-PEG, could effectively manage adverse effects of cisplatin, regardless they 
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were systemically or locally administered [97, 98]. PLA-PEG nanoparticles resulted more effective than free-drug solution 
to reduce the degeneration of both hair cells and stria vascularis, inflammation processes and auditory dysfunctions in 
Guinea pig models. In addition, after intra-tympanic administration, they could improve the drug residence time in the 
perilymph, suggesting nanocarriers could be advantageously proposed also to reduce the drug regimen [99].  
To improve the effectiveness of nanocarriers in delivering drug to the therapeutic site, the performances of ligand-
functionalized nanoparticles were also investigated. Yoon and colleagues demonstrated that arginine-rich peptides improved 
the permeation of dexamethasone-loaded polyplexes in cochlear cells, inducing gene expression and anti-inflammatory 
effect [103]. Accordingly, another cell-penetrating peptide (i.e., PepFect6) resulted effective in favoring the escape of 
siRNA loaded polyplexes from the endosomal compartment after cellular uptake in cochlear organotypic culture [110]. 
Starting from these interesting results on polyplexes, the surface of PCL-PEG nanoparticles was functionalized by a nerve 
growth factor-derived peptide, demonstrating to favor the in vitro target to the cells involved in the neuronal signaling [111]. 
Conversely, other cell-penetrating peptides appeared ineffective in targeting lipid nanocapsules as demonstrated by 
Glueckert and co-workers [106]. Nevertheless, the same authors suggested that antibodies for tyrosine kinase B receptor 
can effectively improve the in vitro biodistribution and interaction of functionalized silica nanoparticles with positive cell 
lines in cochlear cell lines [106]. 
6.3 Nanocarrier-loaded hydrogels 
Despite the encouraging results obtained in vitro by nanocarriers and the feasibility of their safe administration through the 
intra-tympanic route, their residence time in the tympanic cavity remained a critical issue as well as conventional solutions. 
Thus, to solve this limitation and the possible safety issues related to the administration of too large volume of hydrogel, 
the combination of these delivery systems seems a very promising strategy. Indeed, the addition of a nanocarrier can solve 
the issues related to drug loading of the hydrogel, resulting in a significant reduction of the administered volume and in the 
prolongation of therapeutic drug concentrations in the cochlea, even when the formulation is washed-out from the middle 
ear cavity [116]. Conversely, the viscosity of the hydrogel can improve the resistance time of loading nanosystems in the 
tympanic cavity. As a consequence, the nanocarrier can benefit by the increase of the resistance time that favors the partition 
in the OWM or RWM. Although few information is available in literature, some interesting results can be found on the 
topic [116, 121]. El Kechai and co-workers demonstrated the feasibility of a nanocarrier-loaded hydrogel formulation for 
intra-tympanic administration [122]. Liposomes were loaded in a hyaluronic hydrogel and their composition and 
concentration were rationalized to obtain a final semi-solid preparation with suitable viscosity and elasticity to be injectable. 
The optimized formulation was used to delivery dexamethasone in cochlea via intra-tympanic injection. The use of a high 
viscous hyaluronic acid hydrogel as vehicle permitted to prolong the formulation persistence in the middle ear up to 30 
days. When dexamethasone-loaded plain hydrogel (150μL) was injected in tympanic cavity, drug concentrations were 
detectable in perilymph up to 15 days. Conversely, when liposome-loaded hydrogel was used, the sustained delivery of 
dexamethasone was prolonged up to 30 days, even if the volume deposited in the RWM niche was three-time lower. Indeed, 
the results showed that a smaller fraction of intact liposomes in the perilymph, where a great amount of them was retained 
in the RWM, forming a depot able to sustain the drug release [116]. It also permitted to reach perilymphatic drug 
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concentrations that were very close to the therapeutic level without any negative effects on the hearing functions. Similar 
results were observed using chitosan hydrogel as vehicle for liposomes [121]. After deposition of hydrogel in the RWM 
niche, liposomes could diffuse in perilymph and reach the hair cells in mouse model. 
7 Conclusion 
The better knowledge of the etiopathological mechanisms underlying cochlear diseases and the development of procedures 
for the intra-tympanic drug administration permitted attributing possible new therapeutic indications for well-known active 
compounds. Indeed, beside the widely use of steroidal anti-inflammatory drugs, antioxidants and other substances were 
demonstrated to be in vivo effective to prevent the degeneration of organ of Corti cells after exposure to several toxic 
stimuli, providing a proof-of-concepts of their clinical use in humans. 
Nevertheless, several issues related to the biopharmaceutical limitations of cochlea still remain on the round. Indeed, since 
the intra-tympanic injection is invasive and requires specialized medical personal, the frequency of drug administration 
should be minimized, taking however into account that a continuous fluid drainage from the tympanic cavity exists and may 
limit the drug residence time at the RWM surface. Moreover, the permeation of the drug through the RWM has to be assured 
to guarantee its distribution within the cochlea. Among the proposed technological approaches to overcome these issues, 
the development of nanocarriers-loaded hydrogels appears the most promising. However, the impact of physicochemical 
properties of vehicles on their injectability, residence time and permeation of nanocarriers through RWM should be further 
investigated. Moreover, a better characterization of the biopharmaceutical performances and stability of nanocarriers in the 
cochlear fluids is highly desirable because of many evidences suggested their tendency to aggregate after cochlear 
biodistribution. 
Among the studied nanocarriers, the liposomes appear maybe as the most attractive nanocarriers both for intracochlear and 
intratympanic injection. Indeed, their high biodegradability, low toxicity and antigenicity, along with their relatively easy 
metabolization in vivo are advantageous attributes to sustain their intracochlear/intratympanic application. Moreover, they 
can encapsulate different kind of therapeutics (i.e., steroids [123], chemotherapy drugs [124] and nucleic acids [125, 126]) 
with very different physicochemical properties (hydrophilic, lipophilic and amphipathic molecules). In addition, recent 
literature evidences suggested that liposome penetrated RWM, forming drug reservoir that could extend the drug release. It 
may be also underlined that liposome properties can be easily modulated in terms of dimension, surface charge and fluidity 
to optimize the permeation performances through the RMW membrane and distribution in cochlear scala. Moreover, the 
liposomal surface can be properly coated with targeting agents to promoting active permeation through RWM and cellular 
targeting. 
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Table 1 – Studies supporting the efficacy of drugs and drug delivery systems in in vitro models of cochlear cell lines. 
 
Drug/Delivery System Toxic agent In vitro models Main results Ref. 
α-tocopherol succinate Cisplatin Organ of Corti cells Pre-treatment α-tocopherol succinate protected was protective against 
cisplatin-induced cytotoxicity 
[52]  
Flunarizine Cisplatin Organ of Corti cells Flunarizine was protective against cisplatin toxicity, inhibiting lipid 
peroxidation and mitochondrial membrane permeability transition 
[68]  
siRNA-loaded lipofection vectors 
or PLGA nanocarriers 
Neomycin Cochlear tissue explant The down-regulation of HES1 mediated by siRNAs promote the regeneration 
of hair cells 
[76]  
L-ascorbic acid, N-acetylcysteine, 
apocynin 
Neomycin Zebrafish larvae All the tested molecules prevent neomycin-induced ototoxicity, decreasing 
the ROS generation in neuromasts 
[59]  
Mesenchymal-like stem cells Gentamicin Organ of Corti explant 
from neonatal rats 
Restoration of spiral ganglion neurons [80] 
N-acetyl-cysteine Cisplatin Rat auditory air cells and 
neurons 
L-N-acetyl-cysteine was protective against cisplatin toxicity [51]  
Peanut sprout extract Cisplatin Organ of Corti cells Peanut sprout extract protects from cisplatin-induced cytotoxicity by 
activating the antioxidant effects via the Akt/Nrf-2 pathway 
[73]  
Resveratrol Gentamicin Organ of Corti cells Resveratrol was protective against gentamicin toxicity [50]  
Sodium thiosulfate Carboplatin LX-1 human small cell 
lung carcinoma cell 
Sodium thiosulfate blocked carboplatin cytotoxicity [62]  
Rolipram-loaded lipid 
nanocapsules 
Cisplatin Postnatal mouse cochlea 
culture 
The drug-loaded nanocarrier could partially rescue the apoptosis induced by 
cisplatin 
[108] 
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Table 2 – Studies supporting the efficacy of drugs and drug delivery systems in in vivo animal models. 
 
Drug  Delivery System Disease/toxic agent In vivo model 
Administration 
route 
Main results Ref. 
Coenzyme Q10 + 
multivitamin supplement 
Solution Cisplatin Rats Oral Coenzyme Q10 and multivitamin seem to be 
synergic in protecting from the cisplatin-induced 
ototoxicity 
[63]  
Dexamethasone Solution Endolymphatic 
hydrops 
Humans Intra-tympanic Dexamethasone provided efficacy in the treatment 
of contralateral and ipsilateral delayed 
endolymphatic hydrops. 
[46] 
Dexamethasone  Nanocarrier 
(PLA-PEG) 
Cisplatin Guinea pigs Intra-peritoneal The loading of dexamethasone in PEG-PLA 
nanoparticles could enhance the drug protective 
efficacy against cisplatin-induced ototoxicity 
[98] 
Dexamethasone Nanocarrier 
(PLA-PEG) 
Cisplatin Guinea pigs Intra-tympanic Nanoparticles improve the drug penetration through 
local RWM and significantly protected the hair cells 
and auditory function from cisplatin toxicity 
[99] 
Dexamethasone + 
melatonin 
Solution Tinnitus Humans Intra-tympanic Dexamethasone plus melatonin was efficient in 
improvement of idiopathic unilateral tinnitus. 
[47] 
Dexpanthenol Solution Cisplatin Rats Intra-peritoneal Dexpanthenol was effective in preventing cisplatin 
ototoxicity 
[64] 
D-methionine Solution Cisplatin Guinea pigs Intra-venous D-methionine reduced the AUC of cisplatin and was 
protective against cisplatin-ototoxicity 
[58] 
Garlic derivatives Solution Gentamicin Rats Intra-peritoneal Garlic derivatives seemed to attenuate the 
aminoglycoside-induced hearing loss. 
[65]  
Gingko biloba extract 
761 
Not reported Cisplatin Human Oral Ginkgo biloba extract was protective for cisplatin 
ototoxicity 
[61] 
Hepatocyte growth factor Hydrogel 
(gelatin) 
Noise Guinea pig Intra-tympanic Gelatin hydrogel loaded with hepatocyte growth 
factor significantly reduced the noise exposure-
caused ABR threshold shifts and the loss of outer 
hair cells in the basal portion of the cochleae. 
[85] 
Insulin-like growth 
factor-1 
Hydrogel 
(collagen) 
Noise Rats Intra-tympanic Local insulin-like growth factor-1 application 
through the biodegradable hydrogel protected 
cochleae from noise trauma in comparison to 
control. 
[83] 
Insulin-like growth 
factor-1 
Hydrogel 
(gelatin) 
Transient cochlear 
ischemia 
Mongolian gerbils Intra-tympanic Local application of insulin-like growth factor- 
protected cochleae from ischemic injury 
[86] 
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Melatonin Solution Cisplatin Rats Intra-tympanic Melatonin was effective in preventing cisplatin 
ototoxicity 
[66] 
N-Acetylcysteine Solution Cisplatin Guinea pig Intra-tympanic N-Acetylcysteine was protective against cisplatin 
ototoxicity 
[56]  
Neurotrophin 3 Solution Noise Mice Intra-tympanic Regeneration of pre- and postsynaptic elements at 
the hair cell/cochlear nerve interface 
[70] 
NOX3 siRNA Not reported Cisplatin Rats Intra-tympanic siRNA reduced the expression of NOX3 isoform of 
NADPH oxidase, inhibiting the ROS generation 
induced by cisplatin and protecting cochlear 
systems form its toxic effect. 
[75] 
Oxytocin Solution Cisplatin Rats Systemic/intra-
tympanic 
Oxytocin was protective against cisplatin after both 
systemic and intra-tympanic administration 
[67]  
PFT-α Solution Cisplatin Mice Intra-tympanic The p53 inhibitor PFT-α prevented negative effect 
of cisplatin-induced ototoxicity 
[72]  
Resveratrol Solution Cisplatin Rats Intra- peritoneal Resveratrol was protective against cisplatin-
ototoxicity 
[54]  
Resveratrol Solution Noise Rats Oral Resveratrol was protective against acoustic trauma [55]  
Resveratrol Solution Cisplatin Rats Intra- peritoneal Resveratrol was protective against cisplatin-
ototoxicity 
[53] 
Sodium thiosulfate Solution Carboplatin Humans Intra-venous Delayed sodium thiosulfate was effective in 
protecting against carboplatin-induced hearing loss 
[60]  
Sodium thiosulfate Solution Cisplatin Rats Intra-peritoneal Sodium thiosulfate was protective against cisplatin 
in a time-dependent manner 
[57] 
Sodium thiosulfate Solution Carboplatin Guinea pigs Intra-peritoneal Delayed administration of sodium thiosulfate 
resulted effective in reducing cochlear toxicity of 
carboplatin 
[62] 
Stem cells Solution Neomycin Guinea pigs Intra-cochlear Transplanted stem cells were observed at cochlear 
basal membrane. No difference in auditory 
brainstem were observed before and after 
transplantation. 
[81] 
WHRN cDNA Adeno-associated 
virus (AAV8) 
Non-syndromic 
deafness model  
Neonatal mice Intra-cochlear Gene therapy improves hair cell stereocilia 
morphology and increase hair cell survival  
[77] 
 
